Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphatidylinositol glycan anchor biosynthesis class F pseudogene 3 (PIGFP3) is a processed or unprocessed pseudogene related to the phosphatidylinositol glycan anchor biosynthesis class F gene (PIGF). Pseudogenes like PIGFP3 typically resemble protein-coding genes but have accumulated mutations that prevent them from producing a functional protein. Although historically considered nonfunctional "genomic relics," some pseudogenes can impact biological processes at the DNA, RNA, or even peptide/protein level, often via gene regulation rather than direct activity as enzymes, receptors, or transporters[1][2][4]. Such regulatory effects include functioning as antisense RNAs, small interfering RNAs (siRNAs), or competing endogenous RNAs that modulate the expression of their parental genes or participate in complex regulatory networks. However, PIGFP3 is not an established drug or therapeutic target and no direct molecular, clinical, or biomarker roles are reported for it. In scientific and clinical contexts, the main interest in pseudogenes is as potential modulators of disease via indirect gene expression effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphatidylinositol glycan anchor biosynthesis class F pseudogene 3 (PIGFP3).